| IPO Company Profile © ipodata.com |
| Message Board | Quote | Chart | News | SEC Filings | Peer IPO Companies |
| 3-Dimensional Pharmaceuticals, Inc. |
| Eagleview Corporate Center, Suite 104, 665 Stockton Drive, Exton, PA 19341 * (610) 458-8959 |
| Business Description | The Company is a post-genomics drug discovery company that has developed a unique integration of proprietary technologies to provide an accelerated and improved methodology for "gene-to-clinic" small molecule drug discovery. |
| Offering Information Company has | |||
| Trading As | DDDP (NASNTL) | Industry | Pharmaceutical (SIC 2834) |
| Type of Stock Offered | Common Shares | Filing Date | 5/23/00 |
| Domestic Shares Offered | 5,000,000 | Offer Date | 8/3/00 |
| Foreign Shares Offered | 0 | Filing Range | $13.00 - $15.00 |
| Company Shares | 5,000,000 | Offer Price | $15.00 |
| Selling Shrhldrs Shares | 0 | Gross Spread | $1.050 |
| Gross Proceeds | $75,000,000 | Selling | $0.630 |
| Expenses | - - | Reallowance | $0.100 |
| Post-IPO Shares | 18,240,000 | Employees | - - |
| Primary Underwriting Group | ||
| Underwriter Name | Participation | Underwriter Phone |
| Bear, Stearns & Co. Inc. | Lead Manager | (212) 272-4850 |
| Chase H&Q; | Co-manager | (415) 439-3626 |
| U.S. Bancorp Piper Jaffray | Co-manager | (612) 342-6220 |
| Income Statement and Cash Flow Summary | |||||||
| Prior Audited Income |
Latest Unaudited Income | ||||||
| Full Year Audited Figures | 3 Months Ending | ||||||
| Figures in U.S. millions except per share data | 12/31/95 | 12/31/96 | 12/31/97 | 12/31/98 | 12/31/99 | 3/31/99 | 3/31/00 |
| Revenues | 0.463 | 0.967 | 3.580 | 5.095 | 4.489 | 1.379 | 1.484 |
| Income from Oper. | -4.073 | -5.297 | -5.937 | -10.347 | -15.672 | -2.751 | -3.478 |
| Net Income | -4.458 | -5.862 | -5.565 | -9.711 | -15.969 | -2.740 | -3.742 |
| E.P.S | -32.300 | -20.710 | -9.830 | -7.930 | -9.780 | -1.790 | -2.110 |
| Revenue Growth (%) | 108.86 | 270.22 | 42.32 | -11.894 | 7.61 | ||
| Net Income Growth (%) | - | - | - | - | - | ||
| Oper. Profit Margin (%) | - | - | - | - | - | - | - |
| Net Profit Margin (%) | - | - | - | - | - | - | - |
| Cash Flow - Oper. | -10.60 | -5.74 | -3.60 | ||||
| Cash Flow - Inv. | 6.99 | 1.42 | -0.57 | ||||
| Cash Flow - Fin. | 8.79 | -0.32 | 18.59 | ||||
| Balance Sheet Summary and Financial Ratios | |||||
| Balance sheet as of: 3/31/00 | Financial Ratios | ||||
| Total Assets | 27.39 | Current Assets | 22.59 | Current Ratio | 3.83 |
| Total Liab. | 72.17 | Current Liab. | 5.90 | Debt Ratio | 263.44% |
| Total Equity | -44.77 | Working Cap. | 16.70 | Debt to Equity Ratio | - |
| Cash | 22.04 | Return on Assets | - | ||
| Use Of Proceeds |
The proceeds from the proposed offering will be used for research and development, acquisition or licensing of targets or technologies; expansion of our facilities; general corporate and working capital purposes; and possible future acquisitions. |
| Legal Counsel Registrar Auditor | |
| Issuer's Law Firm | Morgan, Lewis & Bockius |
| Bank's Law Firm | Coudert Brothers |
| Auditor | Eisner, Richard A. |
| Send us feedback if you would like to request that we hyperlink a firm on this page | |
| Principal Shareholders | ||
| Name of Shareholder | % Owned Before | % Owned After |
| Healthcare Ventures, funds affiliated with | 29.95 | |
| Biotech Growth SA | 21.01 | |
| Rho Management Trust II | 18.03 | |
| Abingworth Bioventures SICAV | 7.39 | |
| State of Michigan Retirement Systems | 6.25 | |
| Note: represents ownership of 5% or more prior to the offering. | ||